Global Purpura Treatment Market, By Types (Senile Purpura, Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Understand Henoch-Schönlein Purpura, Others), Treatment (Medication, Surgery, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Purpura Treatment Market Analysis and Size
In terms of a fast-growing market, the purpura treatment market has been considered and is also expected to grow at an enormous rate. There is huge demand followed by a seamless flow of the supply chain mechanism in various regions worldwide for purpura treatment. These blood spots are painful and can occur at any age thus, their treatment is gaining popularity.
Data Bridge Market Research analyses a growth rate in the global purpura treatment market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Purpura Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Senile Purpura, Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Understand Henoch-Schönlein Purpura, Others), Treatment (Medication, Surgery, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Purpura is also known as blood spots or skin haemorrhages. It is the type of condition in which purple-coloured spots formed on the skin, the spots are also visible on the organs or mucous membranes, that includes the membranes on the inside of the mouth. Purpura occurs when small blood vessels burst out causing blood clot formation under the skin. Purpura spots are usually benign, but may indicate a more serious medical condition, such as a blood clotting disorder.
Global Purpura Treatment Market Dynamics
Drivers
- Increasing Government Regulations
Governmental initiatives and regulation such as Orphan drug act, U.S., the Orphan Drug Policy Therapeutic Goods Act and Regulations, Australia and the Orphan Drug Regulation, Japan are likely to boost the market during the forecast period. Moreover, increase in R&D expenses from major pharmaceutical companies to develop new treatment options for purpura further drives the market. This boosts the market growth.
- Growing Demand For Combination Therapies
The rising demand for combination therapies is expected to boost the market growth of the purpura treatment drugs. Studies showed that combination therapies have relatively lower side effects, and are cost-effective, and show higher response rates in patients. Some major combination therapies include rituximab and dexamethasone, corticosteroids and IVIG, TPO-RA (eltrombopag), and dexamethasone.
Opportunities
- Increased Partnerships and Collaborations
Major market players are focusing on to launch new products in untapped regions, partnerships, collaborations, and acquisitions are likely to boost the purpura therapy drug market during the forecast period. For instance, in August 2019, Intas Pharmaceuticals Ltd launched a generic version of romiplostim used for the treatment of chronic idiopathic thrombocytopenic purpura (ITP) in India. In 2018, Ablynx gained approval from European Commission to develop Cablivi, a nanobodoy-based medicine. The medicine is one-of-its-kind which, when combined with plasma exchange and immunosuppression, can decrease the time taken by the platelet count to return to normal. Ablynx can acquire a strong hold in the market against its rivals due to this approval. This creates more opportunity for the market growth.
- Increasing Demand for Retail Pharmacies
The increase in the number of drugs for purpura being that is delivered through retail pharmacies and the rise in the number of retail pharmacies in developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Side Effects of Treatments
There are various side-effects associated with the treatment options of purpura. Treatments such as Splenectomy have side effects such as bleeding, blood clots, bleeding, infection. Excessive use of corticosteroids can also lead to side effects such as vomiting, nausea and many others. Thus, this hampers the market growth.
- Lack of Medical Equipments
The growth of the purpura treatment market is likely to be hampered due to the non-availability of medical equipment followed by proper medication for the people who are suffering from the disease. This factor hampers the growth of the market.
This global purpura treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global purpura treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Purpura Treatment Market Scope
The global purpura treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Senile Purpura
- Idiopathic Thrombocytopenic Purpura
- Thrombotic Thrombocytopenic Purpura
- Understand Henoch-Schönlein Purpura
- Others
Treatment
- Medication
- Surgery
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Purpura Treatment Market Regional Analysis/Insights
The global purpura treatment market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global purpura treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global purpura treatment market throughout the forecasted period due to presence of the generic manufacturer.
North America dominates the market due to the presence of key manufacture of the product and high demand of diseases specific treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Purpura Treatment Market Share Analysis
The global purpura treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global purpura treatment market.
Key players operating in the global purpura treatment market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
SKU-